BG100702A - Device and method for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system - Google Patents

Device and method for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system

Info

Publication number
BG100702A
BG100702A BG100702A BG10070296A BG100702A BG 100702 A BG100702 A BG 100702A BG 100702 A BG100702 A BG 100702A BG 10070296 A BG10070296 A BG 10070296A BG 100702 A BG100702 A BG 100702A
Authority
BG
Bulgaria
Prior art keywords
lidocaine
toxic effect
application
vegitative
antagonization
Prior art date
Application number
BG100702A
Other languages
Bulgarian (bg)
Other versions
BG61992B1 (en
Inventor
Страхил Иванов
Original Assignee
Страхил Иванов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Страхил Иванов filed Critical Страхил Иванов
Priority to BG100702A priority Critical patent/BG61992B1/en
Publication of BG100702A publication Critical patent/BG100702A/en
Publication of BG61992B1 publication Critical patent/BG61992B1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

According to this invention the antagonization of the toxiceffect of Lidocaine is attained by the application ofgalantaminechidrobromine (the Nivalin preparation) as an antidoteof Lidocaine. The method for the neutralization of the toxiceffect of Lidocaine on the central and the vegitative nervoussystem consists in fractioned subcutaneous or intravenousapplication of Nivalin at initial dose of 2.5 mg until theachievement of optical therapeutical effect - completeantagonization of the toxic effect of Licodaine. The use ofNivalin for controlling the toxic effect of Lidocaine removes anynecessity for the application of other preparations having adverseeffect on the patient in this state, and for endotrachealintubation and equipment ventilation. The preparation has an easyand convenient scheme of application with the potentials ofcontrolling the critical situation without having any need forspecial complex and expensive equipment and/or specially trainedstaff for resuscitation operations.
BG100702A 1996-07-05 1996-07-05 Device for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system BG61992B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BG100702A BG61992B1 (en) 1996-07-05 1996-07-05 Device for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BG100702A BG61992B1 (en) 1996-07-05 1996-07-05 Device for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system

Publications (2)

Publication Number Publication Date
BG100702A true BG100702A (en) 1998-01-30
BG61992B1 BG61992B1 (en) 1998-12-30

Family

ID=3926646

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100702A BG61992B1 (en) 1996-07-05 1996-07-05 Device for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system

Country Status (1)

Country Link
BG (1) BG61992B1 (en)

Also Published As

Publication number Publication date
BG61992B1 (en) 1998-12-30

Similar Documents

Publication Publication Date Title
CS553490A3 (en) Transdermal therapeutic system
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
AU578428B2 (en) Trace-labeled conjugates of metallothionein and target- seeking biologically active molecules
EP1806131A3 (en) Use of sex steroid function modulators to treat wounds and fibrotic disorders
AU7289694A (en) Three part device for the transdermic administration of drugs by electrophoresis or iontophoresis
MY111188A (en) Improvements in or relating to benzothiophenes.
AU7545594A (en) Implantable device for the treatment of aedemas
MX9605650A (en) Fluticasone propionate formulations.
TW250435B (en)
ES2176415T3 (en) USE OF A COMPOSITION THAT INCLUDES A POLYMER SYSTEM.
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
MX9704037A (en) 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
MXPA94009086A (en) Therapeutic substituted guanidines.
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
EP0744176A3 (en) Methods for inhibiting bone loss
BG102667A (en) Diosgenine-containing composition
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
BG100702A (en) Device and method for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system
NZ324615A (en) Method for treating autism using olanzapine
NO953003L (en) Use of ifenprodil and its diastereoisomers for the preparation of medical preparations
ES2136605T3 (en) ELECTRICAL DEVICE FOR THE TRANSDERMIC APPLICATION OF PHARMACS WITH A COUNTERRESPECT AGENT.